New Tideworks Survey Reveals Need for Practical Data Accuracy and Connectivity at Marine Terminals
SEATTLE, June 18, 2025--(BUSINESS WIRE)--A new global survey from Tideworks Technology® (Tideworks), a full-service provider of comprehensive terminal operating systems (TOS), in partnership with Port Technology International (PTI), reveals key opportunities for practical, real-time and automated data connectivity across marine terminal operations. AI emerged as a top technology priority for large terminals, while terminals of all sizes ranked equipment and asset utilization as the two leading focus areas to improve operations.
The survey gathered responses globally from 121 professionals across container, bulk and roll-on/roll-off terminal operations, with annual throughputs ranging from under 100,000 TEUs to more than five million. Despite widespread adoption of digital tools and automation technologies, terminals still face persistent challenges with data connectivity, system integration and real-time visibility, especially those managing complex operations with lean teams. Operators are looking for connected systems that are easy to use, adaptable to their needs and built for everyday terminals.
"We see marine terminals making bold technology investments, but the next step is ensuring systems work together," said Thomas J. Rucker, President of Tideworks Technology. "What's needed now is smarter connectivity that links data seamlessly across systems, both within the terminal and beyond the gate. Tideworks is committed to meeting terminals where they are, helping them unify their data and operations at their own pace, while giving them the flexibility to explore other emerging technologies on their own terms."
The findings highlight where more connected, real-time systems can deliver the greatest impact for terminal operations.
Yard Optimization is a Top Priority:74% of terminals are focused on reducing unproductive moves and maximizing equipment use. Yard space remains a constraint, with 66% citing it as their top challenge.
Process Automation Leads, Equipment Lags:58% of respondents rank process automation as their priority for technology initiatives, making it the top item in this category. Equipment automation is a lower priority, ranked fifth place with 35%.
Limited Connectivity Hinders Real-Time Insight:86% of respondents utilize TOS and planning tools; however, only 30% leverage real-time analytics. Data sharing is also a barrier—53% face internal integration challenges, and 46% struggle externally. In addition, nearly half (45%) lack real-time visibility.
AI Interest Is Growing, but Data Foundations Must Improve:Among large terminals (1M+ TEUs), 64% are prioritizing AI, compared to 43% of terminals overall. However, 58% of all terminals still rely on manual data practices, highlighting the need for cleaner, more accessible data before advanced technologies can deliver real value.
Tideworks and its leadership team will be at TOC Europe (Booth J50) in Rotterdam from June 17 -19, to share more insights from the survey and showcase its latest solutions designed to unify systems, unlock data and deliver operational optimization in real time.
View full survey insights here: Maritime Terminal Leaders: Tech Innovation and Digitalisation
About Tideworks Technology
Tideworks is a full-service provider of comprehensive terminal operating system solutions for growing marine and intermodal rail terminal operations worldwide. The company helps more than 120 facilities run their operations more efficiently and profitably. From optimized equipment utilization to faster turn times, Tideworks works at every step of terminal operations to maximize productivity and customer service. For more information about Tideworks Technology, a Carrix solution, visit www.tideworks.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250618033319/en/
Contacts
Media Contact Carley Gray, Communiqué PR(206) 282-4923 ext. 114Carley@communiquepr.com
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNN
35 minutes ago
- CNN
How AI can help ease the strain on health care services
CNN's Clare Sebastian visits Philips in the Netherlands, where the company has centered its focus on innovations in the health care tech sector, including the use of artificial intelligence in some of the most commonly used diagnostics tools in the world.
Business Wire
37 minutes ago
- Business Wire
FDA Grants Priority Review for WINREVAIR™ (sotatercept-csrk) to Update Label Based on Results From ZENITH Trial
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted priority review for a new supplemental Biologics License Application (sBLA) seeking approval to update the U.S. product label based on the Phase 3 ZENITH trial for WINREVAIR™ (sotatercept-csrk). In 2024, WINREVAIR was approved for the treatment of adults with pulmonary arterial hypertension (PAH, Group 1 PH) to increase exercise capacity, improve WHO* functional class (FC), and reduce the risk of clinical worsening events. The FDA has set a Prescription Drug User Fee Act (PDUFA), or target action date, of Oct. 25, 2025. The sBLA is based on data from the Phase 3 ZENITH trial. The ZENITH trial was the first PAH Phase 3 outcome study to use a primary endpoint comprised entirely of major morbidity and mortality events. It was also the first PAH Phase 3 study stopped early by an independent data monitoring committee for overwhelming efficacy. In ZENITH, WINREVAIR demonstrated a 76% reduction in the risk of a composite of all-cause death, lung transplantation, and hospitalization for PAH ≥24 hours compared to placebo. Improvement was observed early in treatment with increasing benefit throughout the study. The safety profile of WINREVAIR in ZENITH was generally consistent with that observed in previous studies. These results were published in the New England Journal of Medicine. 'We are pleased that the FDA has accepted our sBLA for WINREVAIR and granted a priority review to consider an update to labeling for WINREVAIR to include the impressive results of ZENITH. There remains a significant unmet medical need for patients living with PAH who, despite being on background therapy, remain at higher risk of morbidity and mortality,' said Dr. Joerg Koglin, senior vice president, global clinical development, Merck Research Laboratories. 'The FDA's Priority Review designation acceptance of our sBLA reinforces our confidence in WINREVAIR for a broad range of patients and represents a critical step toward advancing the treatment of PAH.' WINREVAIR is currently approved in more than 45 countries based on the results from the STELLAR trial. *World Health Organization About ZENITH The ZENITH study (NCT04896008) is a global, double-blind, placebo-controlled clinical trial to evaluate WINREVAIR when added to maximum tolerated background PAH therapy on time to first event of all-cause death, lung transplantation, or PAH worsening related hospitalization of ≥ 24 hours, in adult participants with WHO functional class III or IV PAH at high risk of mortality. ZENITH study inclusion criteria required Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL) Lite 2.0 risk score of ≥9. The study enrolled 172 participants, who were randomized in a 1:1 ratio to either WINREVAIR plus background PAH therapy or placebo plus background PAH therapy. The primary composite outcome measure was time to first confirmed major morbidity or mortality event. Events were defined as all-cause death, lung transplantation, or PAH worsening-related hospitalization of ≥ 24 hours. Secondary outcome measures included overall survival, transplant-free survival and several additional measures. The study excluded patients with PAH Group 1 subtypes: human immunodeficiency virus (HIV)-associated PAH and PAH associated with portal hypertension as well as diagnosis of pulmonary veno-occlusive diseases, pulmonary capillary hemangiomatosis or overt signs of capillary and/or venous involvement. Participants who completed the ZENITH trial were offered the opportunity to receive WINREVAIR as part of the open-label, long-term extension study, SOTERIA (NCT04796337), consistent with that study's eligibility criteria. About WINREVAIR ™ (sotatercept-csrk) for injection, for subcutaneous use, 45 mg, 60 mg WINREVAIR is FDA-approved for the treatment of adults with pulmonary arterial hypertension (PAH, WHO Group 1) to increase exercise capacity, improve WHO functional class (FC) and reduce the risk of clinical worsening events. WINREVAIR is the first activin signaling inhibitor therapy approved to treat PAH. WINREVAIR improves the balance between pro-proliferative and anti-proliferative signaling to modulate vascular proliferation. In preclinical models, WINREVAIR induced cellular changes that were associated with thinner vessel walls, partial reversal of right ventricular remodeling, and improved hemodynamics. WINREVAIR is the subject of a licensing agreement with Bristol Myers Squibb. Selected Safety Information for WINREVAIR in the U.S. WINREVAIR may increase hemoglobin (Hgb). Severe erythrocytosis may increase the risk of thromboembolic events or hyperviscosity syndrome. Monitor Hgb before each dose for the first 5 doses, or longer if values are unstable, and periodically thereafter, to determine if dose adjustments are required. WINREVAIR may decrease platelet count. Severe thrombocytopenia may increase the risk of bleeding. Thrombocytopenia occurred more frequently in patients also receiving prostacyclin infusion. Do not initiate treatment if platelet count is <50,000/mm 3. Monitor platelets before each dose for the first 5 doses, or longer if values are unstable, and periodically thereafter to determine whether dose adjustments are required. In clinical studies, serious bleeding (eg, gastrointestinal, intracranial hemorrhage) was reported in 4% of patients taking WINREVAIR and 1% of patients taking placebo. Patients with serious bleeding were more likely to be on prostacyclin background therapy and/or antithrombotic agents, or have low platelet counts. Advise patients about signs and symptoms of blood loss. Do not administer WINREVAIR if the patient is experiencing serious bleeding. WINREVAIR may cause fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use an effective method of contraception during treatment with WINREVAIR and for at least 4 months after the final dose. Pregnancy testing is recommended for females of reproductive potential before starting WINREVAIR treatment. Based on findings in animals, WINREVAIR may impair female and male fertility. Advise patients on the potential effects on fertility. The most common adverse reactions occurring in the phase 3 clinical trial (≥10% for WINREVAIR and at least 5% more than placebo) were headache (24.5% vs 17.5%), epistaxis (22.1% vs 1.9%), rash (20.2% vs 8.1%), telangiectasia (16.6% vs 4.4%), diarrhea (15.3% vs 10.0%), dizziness (14.7% vs 6.2%), and erythema (13.5% vs 3.1%). Because of the potential for serious adverse reactions in the breastfed child, advise patients that breastfeeding is not recommended during treatment with WINREVAIR, and for 4 months after the final dose. About PAH Pulmonary arterial hypertension (PAH) is a rare, progressive and life-threatening blood vessel disorder characterized by the constriction of small pulmonary arteries and elevated blood pressure in the pulmonary circulation. Approximately 40,000 people in the U.S. are living with PAH. The disease progresses rapidly for many patients. PAH results in significant strain on the heart, leading to limited physical activity, heart failure and reduced life expectancy. The five-year mortality rate for patients with PAH is approximately 43%. About Merck At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn. Forward-Looking Statement of Merck & Co., Inc., Rahway, N.J., USA This news release of Merck & Co., Inc., Rahway, N.J., USA (the 'company') includes 'forward-looking statements' within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company's management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions. The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company's Annual Report on Form 10-K for the year ended December 31, 2024 and the company's other filings with the Securities and Exchange Commission (SEC) available at the SEC's Internet site ( Patient Information for WINREVAIR at , and Instructions for Use for WINREVAIR (1-vial kit, 2-vial kit) at
Forbes
42 minutes ago
- Forbes
Cloudflare Sidesteps Copyright Issues, Blocking AI Scrapers By Default
AI training IT service management company Cloudflare is striking back on behalf of content creators, blocking AI scrapers by default. Web scrapers are bots that crawl the internet, collecting and cataloguing content of all types, and are used by AI firms to collect material that can be used to train their models. Now, though, Cloudflare is allowing website owners to choose if they want AI crawlers to access their content, and decide how the AI companies can use it. They can opt to allow crawlers for certain purposes—search, for example—but block others. AI companies will have to obtain explicit permission from a website before scraping. 'Original content is what makes the internet one of the greatest inventions in the last century, and it's essential that creators continue making it," said Matthew Prince, co-founder and CEO of Cloudflare. "AI crawlers have been scraping content without limits. Our goal is to put the power back in the hands of creators, while still helping AI companies innovate. This is about safeguarding the future of a free and vibrant internet with a new model that works for everyone.' The company's also introducing "pay per crawl"—the ability to charge companies for access. Currently in beta, this facility means that every time an AI crawler requests content, it has to either present payment intent via request headers for successful access, or receive a "402 Payment Required" response with pricing. Users will be able to bypass charges for specific crawlers as needed - useful if they want to allow a certain crawler through for free, or to take part in a content partnership. Crucially, the new measures don't depend on copyright law - currently a legal minefield when it comes to the use of data for AI - but on standard contract law. The move has been welcomed by content owners and creators, with dozens of media organizations and others saying they plan to sign up. 'Cloudflare's innovative approach to block AI crawlers is a game-changer for publishers and sets a new standard for how content is respected online. When AI companies can no longer take anything, they want for free, it opens the door to sustainable innovation built on permission and partnership,' said Roger Lynch, CEO of Condé Nast. 'This is a critical step toward creating a fair value exchange on the Internet that protects creators, supports quality journalism and holds AI companies accountable.' However, with Cloudflare used by millions of organizations around the world, the move looks like bad news for AI companies. 'This long-awaited feature by Cloudflare is a true disaster for many GenAI vendors, which may be fatal to the current business models of GenAI", said Ilia Kolochenko, CEO at ImmuniWeb and an adjunct professor of cybersecurity at Capital Technology University in Maryland. "Most GenAI vendors will soon face a tough reality: paying a fair price for high-quality training data, while staying profitable. In view of the formidable competition emanating from China, many Western GenAI companies may simply quit the business as economically unviable.'
